A severity-based clinical staging model for the psychosis prodrome: Longitudinal findings from the New York recognition and prevention program

Schizophrenia Bulletin

Volumn 43, Issue 1, 2017, Pages 64-74

  Carrión, Ricardo E ^a,b   Correll, Christoph U ^a,c   Auther, Andrea M ^a,c   Cornblatt, Barbara A ^a,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b Northwell Health   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Clinical high risk; Clinical staging; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

4 STAGE MODEL; ADOLESCENT; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL OUTCOME; DISABILITY; DISEASE SEVERITY; EARLY INTERVENTION; FEMALE; HEALTH PROGRAM; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; STAGING; CLASSIFICATION; DISEASE COURSE; FOLLOW UP; PRODROMAL SYMPTOM; PSYCHOTIC DISORDERS; REPRODUCIBILITY; RISK; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; RISK; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 85014222651     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbw155     Document Type: Article

References (51)

1. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand. 1993;87:225-230.
2. McGorry P. A treatment-relevant classification of psychotic disorders. Aust N Z J Psychiatry. 1995;29:555-558.
3. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry. 2006;40:616-622.
4. Huber G, Gross G, Schüttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull. 1980;6:592-605.
5. Sullivan HS. The onset of schizophrenia. Am J Psychiatry. 1927;84:105-134.
6. Conrad K. Die beginnende Schizophrenie: Versuch einer Gestaltanalyse des Wahns. Stuttgart, Germany: Thieme; 1958.
7. Kraepelin E. Manic depressive insanity and paranoia. J Nerv Ment Dis. 1921;53:350.
8. Cameron DE. Early schizophrenia. Am J Psychiatry. 1938;95:567-582.
9. Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. In: Aschaffenburg G, ed. Handbuch der Psychiatrie. Spezieller Teil.
10. Abteilung, 1.Hälfte. Leipzig und Wien: Franz Deuticke; 1911.
11. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50:884-897.
12. McGorry P, Keshavan M, Goldstone S, et al. Biomarkers and clinical staging in psychiatry. World Psychiatry. 2014;13:211-223.
13. McGorry P, Nelson B. Why we need a transdiagnostic staging approach to emerging psychopathology, early diagnosis, and treatment. JAMA Psychiatry. 2016;13:1-2.
14. McGorry PD, Nelson B, Goldstone S, Yung AR. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry. 2010;55:486-497.
15. Agius M, Goh C, Ulhaq S, McGorry P. The staging model in schizophrenia, and its clinical implications. Psychiatr Danub. 2010;22:211-220.
16. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703-715.
17. Fusar-Poli P, Yung AR, McGorry P, van Os J. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol Med. 2014;44:17-24.
18. Cornblatt BA, Carrión RE. Deconstructing the psychosis risk syndrome: moving the field of prevention forward. JAMA Psychiatry. 2016;73:105-106.
19. Fusar-Poli P, Cappucciati M, Borgwardt S, et al. Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. JAMA Psychiatry. 2016;73:113-120.
20. Cornblatt BA. The New York high risk project to the Hillside recognition and prevention (RAP) program. Am J Med Genet. 2002;114:956-966.
21. Cornblatt BA, Carrion RE, Auther A, et al. Psychosis prevention: a modified clinical high risk perspective from the recognition and prevention (RAP) program. Am J Psychiatry. 2015;172:986-994.
22. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull. 2003;29:633-651.
23. Mrazek PJ, Haggerty RJ. Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Washington, DC: National Academies Press; 1994.
24. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660-669.
25. Häfner H, Löffler W, Maurer K, Hambrecht M, an der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatrica Scandinavica. 1999;100:105-118.
26. Carrión RE, McLaughlin D, Goldberg TE, et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry. 2013;70:1133-1142.
27. Hickie IB, Scott EM, Hermens DF, et al. Applying clinical staging to young people who present for mental health care. Early Interv Psychiatry. 2013;7:31-43.
28. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultrahigh risk: randomised controlled trial. Br J Psychiatry. 2004;185:291-297.
29. Morrison AP, French P, Parker S, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull. 2007;33:682-687.
30. Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull. 2006;32:166-178.
31. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159:863-865.
32. Miller TJ, McGlashan TH, Woods SW, et al. Symptom assessment in schizophrenic prodromal states. Psychiatr Q Winter. 1999;70:273-287.
33. Correll CU, Smith CW, Auther AM, et al. Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. J Child Adolesc Psychopharmacol. 2008;18:475-490.
34. Orvaschel H, Puig-Antich J. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version. Fort Lauderdale, FL: Center for Psychological Studies, Nova Southeastern University; 1994.
35. Cornblatt BA, Auther AM, Niendam T, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull. 2007;33:688-702.
36. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
37. Chambers WJ, Puig-Antich J, Hirsch M, et al. The assessment of affective disorders in children and adolescents by semistructured interview. Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version. Arch Gen Psychiatry. 1985;42:696-702.
38. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
39. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: L. Erlbaum Associates; 1988.
40. Mc NQ. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947;12:153-157.
41. Hollingshead AB, Redlich FC. Social Class and Mental Illness. New York, NY: Wiley; 1958.
42. Addington J, Liu L, Perkins D, Carrion RE, Keefe R, Woods SW. The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth with Attenuated Psychotic Symptoms. Schizophr Bull. 2017;43:57-63.
43. Fusar-Poli P, Cappucciati M, De Micheli A, et al. Diagnostic and prognostic significance of Brief Limited Intermittent Psychotic Symptoms in individuals at ultra high risk. Schizophr Bull. 2017;43:48-56.
44. Häfner H. Onset and early course as determinants of the further course of schizophrenia. Acta psychiatrica Scandinavica Supplementum. 2000;102:44-48.
45. Häfner H, Maurer K, an der Heiden W. ABC Schizophrenia study: an overview of results since 1996. Social Psychiatry Psychiatric Epidemiol. 2013;48:1021-1031.
46. Häfner H, Maurer K, Löffler W, an der Heiden W, Hambrecht M, Schultze-Lutter F. Modeling the early course of schizophrenia. Schizophr Bull. 2003;29:325-340.
47. Murphy BP, Stuart AH, McGorry PD. Duration of untreated negative symptoms and duration of active negative symptoms: proof of concepts. Early Interv Psychiatry. 2008;2:27-33.
48. Addington J, Cornblatt BA, Cadenhead KS, et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168:800-805.
49. Carpenter WT. Attenuated psychosis syndrome: need for debate on a new disorder. Psychopathology. 2014;47:287-291.
50. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68:546-557.
51. Fusar-Poli P, Frascarelli M, Valmaggia L, et al. Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychol Med. 2015;45:1327-1339.